China Resources Pharmaceutical Group (01093.HK): JMT101 has been recognized as a breakthrough therapy in China for the treatment of colorectal cancer.

Wisdom financial news app, Shiyao Group (01093.HK) announced that the JMT101 developed by the group has been awarded breakthrough therapy designation by the National Medical Products Administration Drug Evaluation Center of the People's Republic of China. It is proposed to be indicated for the treatment of advanced colorectal cancer with wild-type RAS, RAF, EGFR ECD and PIK3CA20 exons, who have failed second-line or above standard treatment, in combination with Elitorcon.